664. Are Thousands of Medical Cures Hiding in Plain Sight?

Existing drugs can sometimes be repurposed to treat rare diseases. But making that match can be hard — and the financial incentives are weak. Guest host Steve Levitt tries to solve the puzzle. SOURCES: Chris Snyder, professor of economics at Dartmouth College. David Fajgenbaum, co-founder and president of Every Cure, physician-scientist at the University of Pennsylvania. Heather Stone, health science policy analyst at the Food & Drug Administration. Sarrin Chethik, senior policy analyst at the Market Shaping Accelerator. RESOURCES: Chasing My Cure: A Doctor's Race to Turn Hope into Action; A Memoir, by David Fajgenbaum (2019). Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases, by Michael Kremer and Rachel Glennerster (2016). Market Shaping Accelerator. CURE ID Registry. Hosted by Simplecast, an AdsWizz company.